The positive data from the phase II trial of Futura Medical plc.’s (LON:FUM) MED2002 erectile dysfunction gel has been published in the well-respected and peer-reviewed Journal of Sexual Medicine.
The publication is a bit late to the party given that the headline results were announced back in September 2016 but Futura said it nonetheless shows the growing “level of scientific interest” in the gel.
Fast-acting ED treatment
MED2002 met its primary endpoint in the trials by showing a “statistically significant improvement” in erectile function in men with confirmed ED versus a placebo.
The JSM also included further data from the trial, including positive secondary outcome measures which show MED2002 improved orgasmic function, sexual desire, intercourse satisfaction and overall satisfaction.
It also noted that 70% of participants in the study experienced onset of erection within ten minutes on average. Some of the current crop of pills available to ED sufferers can take longer than 20 minutes to kick in.
Publication underlines potential of MED2002
“The publication of the phase II clinical data in the leading, peer-reviewed scientific journal in sexual medicine underlines the robustness of our previously reported study and demonstrates the level of scientific interest in MED2002,” said chief executive James Barder.
“The article, in the Journal of Sexual Medicine, reinforces our belief that MED2002 has the potential to be the world's fastest-acting treatment for erectile dysfunction.”
First phase III trial on track for H1 2018
Barder added that pharmacokinetic study – which is being used to determine the doses used in the upcoming phase III trials – is coming along nicely having kicked off at the end of November.
He also confirmed that the first of the two of those phase III trials is on track to get underway in the first half of this year.